Medico Remedies Ltd
Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual Secretarial Compliance Report confirms full regulatory compliance for FY ended March 2025.
-
Intimation For Commencement Of Work For New Factory Under Regulation 30 (Read With Part B Of Schedule III) (LODR) Regulations, 2015 ("Listing Regulations')
15 May - Medico Remedies starts Rs.30 Cr new factory for antibiotics, adding 25 Cr revenue in 2 years.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 10 May
-
Appointment Of Secretarial Auditor & Approval Of Director''s Report Alongwith Annexures
8 May - Approved FY 2024-25 audited results; appointed new statutory and secretarial auditors for 5 years.
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
8 May - Audited FY25 results with profit growth; new statutory and secretarial auditors appointed subject to shareholder approval.
Business Overview:[1][2]
MRL is a pharmaceutical formulation manufacturing and marketing company with focus on antibiotic, anti-infective, beta-lactam penicillin, cephalosporin, anti fungal, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins & supplements, hematinic and other drugs viz. NSAIDS, antihistaminic, anti-diabetics, cardiovascular drugs, antipyretic, analgesic, diuretics, anti-epileptics, antidepressants, antipsychotics, combination drug kits, dry syrups, ointments and cream & gel for various therapeutic segments